ESMO Breast 2023 | Investigating targeted therapy combinations in metastatic HR+ breast cancer

Komal Jhaveri, MD, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the current and potential therapeutic combinations which aim to improve the median disease-free survival (DFS) in patients with hormone receptor positive (HR+) metastatic breast cancer. Dr Jhaveri recognises the mechanisms of endocrine resistance that can often perturb the use of anti-endocrine therapies, as well as the therapeutic potential that drugs such as CDK4/6 inhibitors, AKT inhibitors, and PI3K targeting agents may hold. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.